Bausch Health Americas, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

197

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 12 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

9 drugs in development

Approved2

Phase 36

Phase 25

Phase 12

Preclinical2

By Therapeutic Area

top 6

Immunology

730%

Respiratory

313%

Dermatology

29%

Neurology

29%

Hematology

29%

Ophthalmology

14%

R&D Momentum

55/100

Pipeline Velocity

22/100

Trial Completion Rate

87/100

Pipeline Concentration

16/100

Pipeline Freshness

53/100

Strategic Signals

↗Active in Dermatology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 1, 2026TrialEfficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Feb 11, 2026TrialRifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Jan 29, 2026TrialStudy to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Oct 2, 2025TrialClindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Feb 21, 2025FDACardizem — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Sep 29, 2023TrialStudy to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

May 18, 2023FDAMiebo — MIEBO

Aug 3, 2022TrialEvaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

4 more events

Apr 7, 2022TrialStudy to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Mar 22, 2022TrialPharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Oct 28, 2021FDACardizem — DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

Oct 22, 2021FDAKenalog — XIPERE

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

36 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dermatology(2 drugs)

—

Dermatology(2 drugs)

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(7 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Neurology(2 drugs)

—

Neurology(2 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Respiratory(3 drugs)

—

Respiratory(3 drugs)

Unknown / Other(3 drugs)

—

Unknown / Other(3 drugs)

Regulatory

Regulatory Timeline

20121 event

FDAMay 11

Tazorac — FABIOR

Application NDA202428 (NDA)

20134 events

FDANov 14

Luzu — LUZU

Application NDA204153 (NDA)

FDAOct 11

Kenalog — NASACORT ALLERGY 24 HOUR

Application NDA020468 (NDA)

FDAAug 13

Vasotec — EPANED KIT

Application NDA204308 (NDA)

FDAApr 5

Bromday — PROLENSA

Application NDA203168 (NDA)

20141 event

FDAJun 6

Jublia — JUBLIA

Application NDA203567 (NDA)

20164 events

FDASep 20

Vasotec — EPANED

Application NDA208686 (NDA)

FDAJul 11

Xiidra — XIIDRA

Application NDA208073 (NDA)

FDAApr 8

Bromday — BROMSITE

Application NDA206911 (NDA)

FDAFeb 29

Tetracaine Hydrochloride — TETRACAINE HYDROCHLORIDE

Application NDA208135 (NDA)

20173 events

FDANov 2

Vyzulta — VYZULTA

Application NDA207795 (NDA)

FDAOct 6

Kenalog — ZILRETTA

Application NDA208845 (NDA)

FDAFeb 15

Siliq — SILIQ

Application BLA761032 (BLA)

20192 events

FDADec 18

Tazorac — ARAZLO

Application NDA211882 (NDA)

FDAMar 12

Tetracaine Hydrochloride — TETRACAINE HYDROCHLORIDE

Application NDA210821 (NDA)

20213 events

FDAOct 28

Cardizem — DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

Application NDA215252 (NDA)

FDAOct 22

Kenalog — XIPERE

Application NDA211950 (NDA)

FDAAug 27

Ativan — LOREEV XR

Application NDA214826 (NDA)

20231 event

FDAMay 18

Miebo — MIEBO

Application NDA216675 (NDA)

20251 event

FDAFeb 21

Cardizem — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Application NDA218038 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)